Guidelines on PSA doubling time

An article in the June issue of the Journal of Urology provides guidelines from a PSA Working Group defining criteria related to the calulation and application of PSA doubling times in monitoring biochemical recurrence and for stratification of patients in clinical trials.

The authors note that calculation of PSA doubling times (PSADT) can be problematic, not least because of assumptions made in determining the methodology for the calculations. They make several specific recommendations designed to standardize the calculation of PSADT.

They also note that the form of intial treatment (surgery, radiation, etc.) will affect the absolute PSA nadir (lowest PSA value) post-treatment, and that this will also impact the calulation of PSADT.

With these reservations, and accepting that the level of available evidence regarding the applicability of PSADT is only level II (as opposed to level I), the Working Group makes the following statements about the role of PSADT as a predictive factor in prostate cancer recurrence:

  • A longer PSADT is associated with a longer time to metastasis, to prostate cancer-specific death, and to death from all causes. Furthermore, as the PSADT increases, so do the time to metastasis and the time to prostate cancer-specific death.
  • Men with a PSADT of < 3 months are are at “extremely high risk for adverse clinical outcomes.”
  • Men with a PSADT of > 15 months have “an extremely low risk of death from prostate cancer.”
  • For men with a PSADT between 3 and 15 months, other clinical factors may have a larger role in determining risk.

With respect to the role of PSADT in stratification of patients for clinical trials, the Working Group makes the following recommendations:

  • Patients who are hormone-naive, with PSA-only failure, and who are entered into clinical trials of novel cytotoxic agents should primarily be those with PSADT < 15 months (approx. 58 percent of this patient group). They should be stratified into three groups, as follows: PSADT < 3 months; PSADT between 3 and 9 months; and PSADT  9 to < 15 months.
  • Patients who have a PSA nadir > 0.2 ng/mL and a PSADT < 3 months when treated with androgen deprivation therapy after radiotherapy or after surgery have a poor prognosis and should be considered for clinical trials, but no formal PSADT stratcification criteria are available.
  • Patients who have androgen-independent prostate cancer (AIPC), no evident metastasis, but a rising PSA should be considered for clinical trials, and should be stratified by PSA kinetics and by PSA concentration, but no formal PSADT stratification criteria are proposed at this time.
  • Patients who have AIPC with evident metastasis should be considered for clinical trials, and stratification by pre-therapy PSADT should be considered.

It is worth noting that some of the same issues are also addressed in a review by Ramirez et al., just published in European Urology. This latter article also addresses issues related to the use of PSADT as a prognostic factor in the expectant management of patients under active surveillance.

4 Responses

  1. My PSA has doubled in 6 months from 96 to 193 ng/ml.

  2. Mr. Severns: If you are looking for some help in knowing what to do, we suggest you join The “New” Prostate Cancer InfoLink Social Network.

  3. I had 3D-CRT in 1998. At the time my PSA was 0.6 with a Gleason score of 6. My PSA nadir was 0.4. In the last 9 months my PSA has gone to 0.7 and 3 months later 0.8. How do I calculate doubling time? How significant is this rising PSA?

  4. Morris:

    You can find a PSA doubling time calculator either here or on the web site of the Memorial Sloan-Kettering Cancer Center (open the calculator and then scroll down until you the link that says “PSA Doubling Time.”)

    The precise significance of your rising PSA needs to be discussed with your doctor because it depends on a variety of factors. However, the longer the PSA doubling time, the less aggressive the recurrence of the cancer can usually be though to be.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: